Aug 31, 2021 | Press Releases
MARLBOROUGH, Mass., Aug. 31, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Aug 12, 2021 | Press Releases
MARLBOROUGH, Mass., Aug. 12, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Jul 7, 2021 | Press Releases
MARLBOROUGH, Mass., July 7, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Jun 22, 2021 | Press Releases
MARLBOROUGH, Mass., June 22, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Jun 14, 2021 | Press Releases
MARLBOROUGH, Mass., June 14, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Jun 4, 2021 | Press Releases
Treatment with INTASYL dual-targeting BRD4 and PD-1, elicits complete tumor responses and evidence of synergy in newly released in vivo study resultsData presented at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingMARLBOROUGH, Mass., June 4, 2021...